Genmab AS
GMAB: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 5,635.00 | Qdnshm | Sgfnxynll |
Genmab: Strong Royalty Revenue From Darzalex Provides Ample Cash Flow; Shares Undervalued
Royalty revenue from Genmab’s Darzalex is continuing to drive sales, accounting for 68% of Genmab’s total revenue in 2023. It’s providing ample cash flow as the company works to develop its pipeline and prioritize commercialization efforts for Epkinly, which received regulatory approvals in the United States, European Union, and Japan for the treatment of diffuse large B-cell lymphoma.